Contineum Therapeutics Future Growth
Future criteria checks 0/6
Contineum Therapeutics's revenue is forecast to decline at 18.6% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | -18.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | N/A | -68 | -68 | 2 |
| 12/31/2025 | 10 | N/A | -42 | -42 | 3 |
| 12/31/2024 | N/A | N/A | -31 | -30 | 3 |
| 9/30/2024 | N/A | -29 | -34 | -33 | N/A |
| 6/30/2024 | N/A | -20 | -33 | -33 | N/A |
| 3/31/2024 | 50 | 0 | 16 | 17 | N/A |
| 12/31/2023 | 50 | 3 | 19 | 19 | N/A |
| 9/30/2023 | 50 | -3 | 26 | 26 | N/A |
| 12/31/2022 | N/A | -24 | -20 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CTNM's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if CTNM's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CTNM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CTNM's revenue is expected to decline over the next 3 years (-18.6% per year).
High Growth Revenue: CTNM's revenue is forecast to decline over the next 3 years (-18.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTNM's Return on Equity is forecast to be high in 3 years time